This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2012 Jul;12(7):498-9.

doi: 10.1016/S1473-3099(12)70061-0. Epub 2012 Mar 16.

Nevirapine-based therapy after suppression: can we switch?

Sharon Nachman¹, James McIntyre

Affiliations

PMID: 22424721
DOI: 10.1016/S1473-3099(12)70061-0

Comment

Nevirapine-based therapy after suppression: can we switch?

Sharon Nachman et al. Lancet Infect Dis. 2012 Jul.

. 2012 Jul;12(7):498-9.

doi: 10.1016/S1473-3099(12)70061-0. Epub 2012 Mar 16.

Authors

Sharon Nachman¹, James McIntyre

Affiliation

¹ Pediatrics, Stony Brook University, Stony Brook, NY, USA. Sharon.nachman@stonybrook.edu

PMID: 22424721
DOI: 10.1016/S1473-3099(12)70061-0

No abstract available

PubMed Disclaimer

Comment on

Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial.
Kuhn L, Coovadia A, Strehlau R, Martens L, Hu CC, Meyers T, Sherman G, Hunt G, Persaud D, Morris L, Tsai WY, Abrams EJ. Kuhn L, et al. Lancet Infect Dis. 2012 Jul;12(7):521-30. doi: 10.1016/S1473-3099(12)70051-8. Epub 2012 Mar 16. Lancet Infect Dis. 2012. PMID: 22424722 Free PMC article. Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information